Lista de obras - Sven Rottenberg - Dominio Público Uruguay

53BP1 cooperation with the REV7–shieldin complex underpins DNA structure-specific NHEJ

artículo científico publicado en 2018

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance

artículo científico publicado en 2010

A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.

artículo científico publicado en 2017

BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance

artículo científico publicado en 2017

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

artículo científico publicado en 2011

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

artículo científico publicado en 2016

BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.

artículo científico publicado en 2014

Cancer cell death by programmed necrosis?

artículo científico publicado en 2004

Characterization of the bovine IkappaB kinases (IKK)alpha and IKKbeta, the regulatory subunit NEMO and their substrate IkappaBalpha.

artículo científico publicado en 2002

CopywriteR: DNA copy number detection from off-target sequence data

artículo científico publicado en 2015

Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer

artículo científico publicado en 2015

Drug resistance in the mouse cancer clinic

artículo científico publicado en 2012

Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin

artículo científico publicado en 2013

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

artículo científico publicado en 2017

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors

artículo científico publicado en 2012

Further evidence for BRCA1 communication with the inactive X chromosome

artículo científico publicado en 2007

Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer

artículo científico publicado en 2016

HELB Is a Feedback Inhibitor of DNA End Resection

scientific journal article

Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents.

artículo científico publicado en 2018

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

artículo científico publicado en 2008

Hijacking of host cell IKK signalosomes by the transforming parasite Theileria

artículo científico publicado en 2002

How do real tumors become resistant to cisplatin?

scientific article published on 17 March 2008

Identification and characterisation of a Theileria annulata proline-rich microtubule and SH3 domain-interacting protein (TaMISHIP) that forms a complex with CLASP1, EB1, and CD2AP at the schizont surface.

artículo científico publicado en 2018

Identifying subgroup markers in heterogeneous populations

artículo científico publicado en 2013

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors

artículo científico publicado en 2012

Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy

artículo científico publicado en 2015

Intra-operative ex vivo photoacoustic nodal staging in a rat model using a clinical superparamagnetic iron oxide nanoparticle dispersion

artículo científico publicado en 2013

Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol

artículo científico publicado en 2012

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors

artículo científico publicado en 2012

MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression

artículo científico publicado en 2012

Minimal residual disease in cancer therapy--Small things make all the difference

artículo científico

Modeling therapy resistance in genetically engineered mouse cancer models

artículo científico publicado en 2007

Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer

article

Monitoring of tumor response to Cisplatin using optical spectroscopy

artículo científico publicado en 2014

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.

artículo científico publicado en 2018

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model

artículo científico publicado en 2017

New tools for old drugs: Functional genetic screens to optimize current chemotherapy.

artículo científico publicado en 2018

Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity

artículo científico publicado en 2008

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells

artículo científico publicado en 2017

Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance

artículo científico publicado en 2013

Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer

artículo científico publicado en 2012

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

artículo científico publicado en 2022

Questioning the value of 99mTc-HYNIC-annexin V based response monitoring after docetaxel treatment in a mouse model for hereditary breast cancer

artículo científico publicado en 2010

REV7 counteracts DNA double-strand break resection and affects PARP inhibition

artículo científico publicado en 2015

Real-Time In Vivo Characterization of Primary Liver Tumors With Diffuse Optical Spectroscopy During Percutaneous Needle Interventions: Feasibility Study in Woodchucks.

artículo científico publicado en 2015

Replication fork stability confers chemoresistance in BRCA-deficient cells

artículo científico publicado en 2016

Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model

artículo científico publicado en 2015

Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer

scientific article published on 23 August 2016

Selected alkylating agents can overcome drug tolerance of G0-like tumor cells and eradicate BRCA1-deficient mammary tumors in mice

artículo científico publicado en 2017

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

scientific article published on 01 June 2018

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

artículo científico publicado en 2007

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.

artículo científico publicado en 2015

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan

artículo científico publicado en 2010

Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs

artículo científico publicado en 2015

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity

scientific article published in Nature Communications

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

artículo científico publicado en 2018

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models

artículo científico publicado en 2016

The rediscovery of platinum-based cancer therapy

artículo científico publicado en 2020

The shieldin complex mediates 53BP1-dependent DNA repair

scientific article published in Nature

Theileria-induced leukocyte transformation

artículo científico publicado en 2003

Therapeutic options for triple-negative breast cancers with defective homologous recombination

artículo científico publicado en 2009

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo

artículo científico publicado en 2010

What makes tumors multidrug resistant?

artículo científico publicado en 2007

Lista de obras de Sven Rottenberg

53BP1 cooperation with the REV7–shieldin complex underpins DNA structure-specific NHEJ

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance

A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.

BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1

BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.

Cancer cell death by programmed necrosis?

Characterization of the bovine IkappaB kinases (IKK)alpha and IKKbeta, the regulatory subunit NEMO and their substrate IkappaBalpha.

CopywriteR: DNA copy number detection from off-target sequence data

Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer

Drug resistance in the mouse cancer clinic

Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors

Further evidence for BRCA1 communication with the inactive X chromosome

Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer

HELB Is a Feedback Inhibitor of DNA End Resection

Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Hijacking of host cell IKK signalosomes by the transforming parasite Theileria

How do real tumors become resistant to cisplatin?

Identification and characterisation of a Theileria annulata proline-rich microtubule and SH3 domain-interacting protein (TaMISHIP) that forms a complex with CLASP1, EB1, and CD2AP at the schizont surface.

Identifying subgroup markers in heterogeneous populations

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors

Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy

Intra-operative ex vivo photoacoustic nodal staging in a rat model using a clinical superparamagnetic iron oxide nanoparticle dispersion

Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors

MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression

Minimal residual disease in cancer therapy--Small things make all the difference

Modeling therapy resistance in genetically engineered mouse cancer models

Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer

Monitoring of tumor response to Cisplatin using optical spectroscopy

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model

New tools for old drugs: Functional genetic screens to optimize current chemotherapy.

Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells

Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance

Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Questioning the value of 99mTc-HYNIC-annexin V based response monitoring after docetaxel treatment in a mouse model for hereditary breast cancer

REV7 counteracts DNA double-strand break resection and affects PARP inhibition

Real-Time In Vivo Characterization of Primary Liver Tumors With Diffuse Optical Spectroscopy During Percutaneous Needle Interventions: Feasibility Study in Woodchucks.

Replication fork stability confers chemoresistance in BRCA-deficient cells

Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model

Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer

Selected alkylating agents can overcome drug tolerance of G0-like tumor cells and eradicate BRCA1-deficient mammary tumors in mice

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan

Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models

The rediscovery of platinum-based cancer therapy

The shieldin complex mediates 53BP1-dependent DNA repair

Theileria-induced leukocyte transformation

Therapeutic options for triple-negative breast cancers with defective homologous recombination

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo

What makes tumors multidrug resistant?